QQQ   416.27 (-1.69%)
AAPL   164.62 (-1.45%)
MSFT   398.90 (-1.33%)
META   481.97 (-3.95%)
GOOGL   153.12 (-1.85%)
AMZN   174.66 (-2.54%)
TSLA   148.65 (-0.85%)
NVDA   810.00 (-4.34%)
AMD   148.61 (-4.17%)
NIO   3.82 (-4.50%)
BABA   68.57 (-0.45%)
T   16.33 (+0.00%)
F   12.08 (+0.17%)
MU   106.92 (-4.48%)
GE   148.19 (-3.11%)
CGC   8.02 (+2.43%)
DIS   111.78 (-0.58%)
AMC   3.26 (+11.64%)
PFE   25.77 (+1.50%)
PYPL   61.98 (-0.19%)
XOM   119.94 (+1.20%)
QQQ   416.27 (-1.69%)
AAPL   164.62 (-1.45%)
MSFT   398.90 (-1.33%)
META   481.97 (-3.95%)
GOOGL   153.12 (-1.85%)
AMZN   174.66 (-2.54%)
TSLA   148.65 (-0.85%)
NVDA   810.00 (-4.34%)
AMD   148.61 (-4.17%)
NIO   3.82 (-4.50%)
BABA   68.57 (-0.45%)
T   16.33 (+0.00%)
F   12.08 (+0.17%)
MU   106.92 (-4.48%)
GE   148.19 (-3.11%)
CGC   8.02 (+2.43%)
DIS   111.78 (-0.58%)
AMC   3.26 (+11.64%)
PFE   25.77 (+1.50%)
PYPL   61.98 (-0.19%)
XOM   119.94 (+1.20%)
QQQ   416.27 (-1.69%)
AAPL   164.62 (-1.45%)
MSFT   398.90 (-1.33%)
META   481.97 (-3.95%)
GOOGL   153.12 (-1.85%)
AMZN   174.66 (-2.54%)
TSLA   148.65 (-0.85%)
NVDA   810.00 (-4.34%)
AMD   148.61 (-4.17%)
NIO   3.82 (-4.50%)
BABA   68.57 (-0.45%)
T   16.33 (+0.00%)
F   12.08 (+0.17%)
MU   106.92 (-4.48%)
GE   148.19 (-3.11%)
CGC   8.02 (+2.43%)
DIS   111.78 (-0.58%)
AMC   3.26 (+11.64%)
PFE   25.77 (+1.50%)
PYPL   61.98 (-0.19%)
XOM   119.94 (+1.20%)
QQQ   416.27 (-1.69%)
AAPL   164.62 (-1.45%)
MSFT   398.90 (-1.33%)
META   481.97 (-3.95%)
GOOGL   153.12 (-1.85%)
AMZN   174.66 (-2.54%)
TSLA   148.65 (-0.85%)
NVDA   810.00 (-4.34%)
AMD   148.61 (-4.17%)
NIO   3.82 (-4.50%)
BABA   68.57 (-0.45%)
T   16.33 (+0.00%)
F   12.08 (+0.17%)
MU   106.92 (-4.48%)
GE   148.19 (-3.11%)
CGC   8.02 (+2.43%)
DIS   111.78 (-0.58%)
AMC   3.26 (+11.64%)
PFE   25.77 (+1.50%)
PYPL   61.98 (-0.19%)
XOM   119.94 (+1.20%)

Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
$1.16
$1.15
$0.98
$1.89
$36.26M-0.6866,385 shs4,851 shs
Health Sciences Acquisitions Co. 2 stock logo
HSAQ
Health Sciences Acquisitions Co. 2
$4.71
+1.9%
$5.71
$9.41
$13.80
$52.81M0.09205,918 shs30,144 shs
Profound Medical Corp. stock logo
PROF
Profound Medical
$7.33
-6.5%
$8.37
$7.11
$15.49
$179.07M0.841,731 shs34,571 shs
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
$3.27
+0.6%
$3.90
$1.79
$5.38
$53.60M0.91150,673 shs72,868 shs
20 Stocks to Sell Now Cover

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
+1.75%-6.45%+5.45%-4.92%-22.15%
Health Sciences Acquisitions Co. 2 stock logo
HSAQ
Health Sciences Acquisitions Co. 2
+1.95%-6.73%-11.13%-37.45%-76.19%
Profound Medical Corp. stock logo
PROF
Profound Medical
+0.38%-5.54%-5.08%-2.24%-34.99%
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
0.00%+3.50%-15.58%+24.52%-35.64%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
2.7393 of 5 stars
3.02.00.04.40.60.00.6
Health Sciences Acquisitions Co. 2 stock logo
HSAQ
Health Sciences Acquisitions Co. 2
N/AN/AN/AN/AN/AN/AN/AN/A
Profound Medical Corp. stock logo
PROF
Profound Medical
1.5591 of 5 stars
3.52.00.00.02.30.80.6
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
2.9664 of 5 stars
3.55.00.00.02.20.81.3

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
2.00
Hold$2.50115.52% Upside
Health Sciences Acquisitions Co. 2 stock logo
HSAQ
Health Sciences Acquisitions Co. 2
N/AN/AN/AN/A
Profound Medical Corp. stock logo
PROF
Profound Medical
3.00
Buy$14.5898.95% Upside
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
3.00
Buy$7.50129.36% Upside

Current Analyst Ratings

Latest PROF, CODX, SRTS, and HSAQ Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
3/15/2024
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$3.00 ➝ $2.50
(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
$6.81M5.32N/AN/A$2.81 per share0.41
Health Sciences Acquisitions Co. 2 stock logo
HSAQ
Health Sciences Acquisitions Co. 2
N/AN/AN/AN/A($0.62) per shareN/A
Profound Medical Corp. stock logo
PROF
Profound Medical
$7.20M24.87N/AN/A$1.28 per share5.73
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
$24.41M2.20$0.06 per share56.28$2.98 per share1.10

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
-$35.33M-$1.21N/AN/A-518.69%-35.37%-32.58%5/9/2024 (Estimated)
Health Sciences Acquisitions Co. 2 stock logo
HSAQ
Health Sciences Acquisitions Co. 2
-$380KN/A0.00N/AN/AN/A-2.38%N/A
Profound Medical Corp. stock logo
PROF
Profound Medical
-$28.57M-$1.35N/AN/AN/A-396.85%-70.18%-53.80%5/8/2024 (Estimated)
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
$490K$0.03109.04N/A1.99%1.04%0.93%5/9/2024 (Confirmed)

Latest PROF, CODX, SRTS, and HSAQ Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/9/2024N/A
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
-$0.04N/A+$0.04N/AN/AN/A  
3/14/2024Q4 2023
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
N/A-$0.50-$0.50-$0.50$3.63 million$3.56 million
3/7/2024Q4 2023
Profound Medical Corp. stock logo
PROF
Profound Medical
-$0.28-$0.42-$0.14-$0.42$1.90 million$2.01 million
2/8/2024Q4 2023
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
$0.12$0.26+$0.14$0.26$12.10 million$12.57 million

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
N/AN/AN/AN/AN/A
Health Sciences Acquisitions Co. 2 stock logo
HSAQ
Health Sciences Acquisitions Co. 2
N/AN/AN/AN/AN/A
Profound Medical Corp. stock logo
PROF
Profound Medical
N/AN/AN/AN/AN/A
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
N/A
10.81
10.52
Health Sciences Acquisitions Co. 2 stock logo
HSAQ
Health Sciences Acquisitions Co. 2
N/A
0.17
0.61
Profound Medical Corp. stock logo
PROF
Profound Medical
0.16
6.58
5.48
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
N/A
11.76
8.23

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
14.99%
Health Sciences Acquisitions Co. 2 stock logo
HSAQ
Health Sciences Acquisitions Co. 2
89.71%
Profound Medical Corp. stock logo
PROF
Profound Medical
47.86%
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
25.30%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Co-Diagnostics, Inc. stock logo
CODX
Co-Diagnostics
15531.26 million30.51 millionOptionable
Health Sciences Acquisitions Co. 2 stock logo
HSAQ
Health Sciences Acquisitions Co. 2
411.21 million8.76 millionNot Optionable
Profound Medical Corp. stock logo
PROF
Profound Medical
13124.43 million24.06 millionOptionable
Sensus Healthcare, Inc. stock logo
SRTS
Sensus Healthcare
3516.39 million14.57 millionOptionable

PROF, CODX, SRTS, and HSAQ Headlines

SourceHeadline
Sensus Healthcare to Host First Quarter 2024 Financial Results and Business Update Conference Call on Thursday, May 9, 2024Sensus Healthcare to Host First Quarter 2024 Financial Results and Business Update Conference Call on Thursday, May 9, 2024
globenewswire.com - April 18 at 4:05 PM
Sensus Healthcare, Inc. (NASDAQ:SRTS) Short Interest UpdateSensus Healthcare, Inc. (NASDAQ:SRTS) Short Interest Update
americanbankingnews.com - April 11 at 5:40 AM
Sensus Healthcare, Inc. (NASDAQ:SRTS) Sees Large Increase in Short InterestSensus Healthcare, Inc. (NASDAQ:SRTS) Sees Large Increase in Short Interest
marketbeat.com - March 28 at 11:58 AM
Sensus Healthcare Inc.Sensus Healthcare Inc.
wsj.com - March 23 at 2:11 AM
Sensus Healthcare to Participate in the 36th Annual Roth ConferenceSensus Healthcare to Participate in the 36th Annual Roth Conference
globenewswire.com - March 14 at 4:05 PM
Sensus Healthcare Launches “Fair Deal Agreement” for its SRT-100 Vision™ at the American Academy of Dermatology Annual MeetingSensus Healthcare Launches “Fair Deal Agreement” for its SRT-100 Vision™ at the American Academy of Dermatology Annual Meeting
globenewswire.com - March 13 at 8:00 AM
A Market With a HangoverA Market With a Hangover
realmoney.thestreet.com - March 11 at 1:19 PM
3 Stocks to Buy That Are Up 100% or More in 20243 Stocks to Buy That Are Up 100% or More in 2024
investorplace.com - February 25 at 2:02 PM
Sensus Healthcare (SRTS) Price Target Increased by 24.07% to 6.83Sensus Healthcare (SRTS) Price Target Increased by 24.07% to 6.83
msn.com - February 24 at 4:42 AM
Sensus Healthcare Stock (NASDAQ:SRTS) Earnings Dates and Earning CallsSensus Healthcare Stock (NASDAQ:SRTS) Earnings Dates and Earning Calls
benzinga.com - February 23 at 5:28 PM
My Current Game Plan Includes Adding This Small-Cap Stock to My Watch ListMy Current Game Plan Includes Adding This Small-Cap Stock to My Watch List
realmoney.thestreet.com - February 21 at 8:19 PM
Integer Holdings Corporation (ITGR) Soars to 52-Week High, Time to Cash Out?Integer Holdings Corporation (ITGR) Soars to 52-Week High, Time to Cash Out?
finance.yahoo.com - February 12 at 12:53 PM
Sensus Healthcare, Inc. Beat Analyst Profit Forecasts, And Analysts Have New EstimatesSensus Healthcare, Inc. Beat Analyst Profit Forecasts, And Analysts Have New Estimates
finance.yahoo.com - February 11 at 10:42 AM
Sensus Healthcare: Strong Q4 Performance and Promising Future Drive Buy RatingSensus Healthcare: Strong Q4 Performance and Promising Future Drive Buy Rating
markets.businessinsider.com - February 10 at 3:48 PM
Sensus Healthcare, Inc. (SRTS) Q4 2023 Earnings Call TranscriptSensus Healthcare, Inc. (SRTS) Q4 2023 Earnings Call Transcript
seekingalpha.com - February 9 at 7:12 PM
Sensus Healthcare, Inc. (NASDAQ:SRTS) Q4 2023 Earnings Call TranscriptSensus Healthcare, Inc. (NASDAQ:SRTS) Q4 2023 Earnings Call Transcript
finance.yahoo.com - February 9 at 2:11 PM
Q4 2023 Sensus Healthcare Inc Earnings CallQ4 2023 Sensus Healthcare Inc Earnings Call
finance.yahoo.com - February 9 at 9:10 AM
Sensus Healthcare Reports Fourth Quarter and Full Year 2023 Financial ResultsSensus Healthcare Reports Fourth Quarter and Full Year 2023 Financial Results
markets.businessinsider.com - February 8 at 7:56 PM
Sensus Healthcare announces U.S. patent for SRT-100 Vision SystemSensus Healthcare announces U.S. patent for SRT-100 Vision System
msn.com - February 8 at 9:55 AM
Sensus Healthcare Issued U.S. Patent for SRT-100 Vision® System (IG-SRT) CapabilitiesSensus Healthcare Issued U.S. Patent for SRT-100 Vision® System (IG-SRT) Capabilities
finance.yahoo.com - February 8 at 9:55 AM
Earnings Preview For Sensus HealthcareEarnings Preview For Sensus Healthcare
benzinga.com - February 7 at 3:46 PM
Sensus Healthcare Collaborates with CureRays to Provide Oversight to Help Customers Assure Patient Safety, Reliability of Outcomes and Conformance with Regulatory RequirementsSensus Healthcare Collaborates with CureRays to Provide Oversight to Help Customers Assure Patient Safety, Reliability of Outcomes and Conformance with Regulatory Requirements
finance.yahoo.com - February 6 at 1:04 PM
Sensus Healthcare Announces Director Samuel O’Rear’s RetirementSensus Healthcare Announces Director Samuel O’Rear’s Retirement
msn.com - February 3 at 9:40 AM
Apple, Amazon and Meta Will Tell Us a Lot About This Markets HealthApple, Amazon and Meta Will Tell Us a Lot About This Market's Health
realmoney.thestreet.com - February 2 at 12:48 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

All Headlines

Company Descriptions

Co-Diagnostics logo

Co-Diagnostics

NASDAQ:CODX
Co-Diagnostics, Inc., a molecular diagnostics company, develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. The company offers Co-Dx PCR platform, a polymerase chain reaction (PCR) testing to patients in point-of-care and at-home setting. It also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, human papillomavirus, malaria, chikungunya, dengue, and the zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. The company was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Health Sciences Acquisitions Co. 2 logo

Health Sciences Acquisitions Co. 2

NASDAQ:HSAQ
Health Sciences Acquisitions Corporation 2 does not have significant operations. It intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or related business combination with one or more businesses in the biopharma and medical technology sectors in North America or Europe. Health Sciences Acquisitions Corporation 2 was incorporated in 2020 and is based in New York, New York.
Profound Medical logo

Profound Medical

NASDAQ:PROF
Profound Medical Corp., together with its subsidiaries, operates as a commercial-stage medical device company that develops and markets incision-free therapeutic systems for the image guided ablation of diseased tissue in Canada, Germany, the United States, and Finland. Its lead product TULSA-PRO system combines magnetic resonance imaging(MRI), robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to provide precise, flexible, and durable ablation of a surgeon defined region of prostate and protect the urethra and rectum. The company also offers Sonalleve, which combines real-time MRI and thermometry for the treatment of uterine fibroids, adenomyotic tissue, palliative pain treatment of bone metastases, osteoid osteoma, and management of benign tumors. Profound Medical Corp. is headquartered in Mississauga, Canada.
Sensus Healthcare logo

Sensus Healthcare

NASDAQ:SRTS
Sensus Healthcare, Inc., a medical device company, manufactures and sells radiation therapy devices to healthcare providers worldwide. The company uses superficial radiation therapy, a low-energy X-ray technology in its portfolio of treatment devices. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers, as well as other skin conditions, such as keloids; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates an embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters. The company also provides SRT-100 Plus; Sentinel service program, which offers its customers protection for their systems; and Transdermal Infusion system, a biophysical alternative to infuse high weight molecule modalities into the dermis for medical and aesthetic purposes without the use of needles. In addition, it sells disposable lead shielding replacements; and disposable radiation safety items, such as aprons and eye shields, ultrasound probe film, and disposable applicator tips to treat various sized lesions and various areas of the body. Further, the company distributes laser devices, which includes applications for hair removal, vascular lesions, acne treatment, skin toning, and skin rejuvenation, as well as epidermal pigment removal for spots, freckles, and tattoos. It markets its products primarily to private dermatology practices, and radiation oncologists in both private and hospital settings. Sensus Healthcare, Inc. was incorporated in 2010 and is headquartered in Boca Raton, Florida.